Global Bronchiectasis Drugs Market
Sizing, Segmentation, & Growth Forecast (2025-2030)
Last updated: August 2026
Report Scope: The downloadable datasheet contains market sizes in USD for the period 2025-30.
Market Breakdown: Sizes and growth rates are broken down by geography and market segment (see below for details).
1. Summary
The Global Bronchiectasis Drugs Market was valued at $2.1 bn. in 2025. During the forecast period 2025-2030, it is expected to grow at 9.5% CAGR, to an estimated market size of $3.4 bn. in 2030. A detailed breakdown by segment and geography is provided in the downloadable datasheet.
2. Market Definition
The global bronchiectasis drugs market comprises pharmaceutical interventions designed to manage and treat chronic airway dilation, including antibiotics (oral and inhaled), mucolytics, bronchodilators, and emerging anti-inflammatory biologics. The scope includes treatments for both cystic fibrosis-related and non-cystic fibrosis bronchiectasis (NCFB), focusing on reducing exacerbation frequency, managing chronic infections, and improving mucociliary clearance.
3. Trends & Demand Drivers
Several key trends are expected to significantly impact the Bronchiectasis Drugs Market in the period 2025-30:
- The anticipated regulatory approval and launch of first-in-class disease-modifying therapies, such as Brensocatib, are expected to significantly shift the market from off-label management to targeted treatment.
- There is an increasing clinical preference for inhaled antibiotics over systemic delivery to achieve higher local drug concentrations in the lungs while minimizing systemic side effects.
- Advancements in High-Resolution Computed Tomography (HRCT) and AI-driven imaging analysis are improving early diagnosis rates and enabling more accurate monitoring of bronchial dilation.
- The market is transitioning toward precision medicine, utilizing clinical biomarkers and microbiology-guided prescribing to tailor treatments to specific patient phenotypes and endotypes.
- Rising global prevalence of chronic respiratory diseases and an aging population are expanding the primary patient pool for bronchiectasis therapeutics.
- Strategic R&D investments are increasingly focused on addressing unmet needs in neutrophilic airway inflammation and chronic Pseudomonas aeruginosa infections.
- Integration of digital health tools, including smart inhalers and connected nebulizers, is enhancing patient adherence and enabling predictive management of pulmonary exacerbations.
4. Market Breakdown
The downloadable datasheet breaks market sizes and growth rates (CAGRs) down into the following geographies and segments:
Geographies
- North America
- Europe
- Asia-Pacific
- Rest of World
Segments
- Antibiotics
- Mucolytics & Bronchodilators
- Novel Anti-inflammatories & Biologics